CTOs on the Move

Scientific Protein Laboratories

www.spl-pharma.com

 
For nearly three decades we have been a world leader in the production of bulk Heparin and Pancreatin for the pharmaceutical industry. We have been instrumental in the manufacture and development of pharmaceutical ingredients that have made an enormous
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Systems Assessment and Research

Systems Assessment and Research is a Lanham, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

P23 Labs

Get tested for a healthier lifestyle. We offer at-home genetic test for fitness, health and even food sensitivities. Test your DNA today!

URAC

URAC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Child Health Corporation Of America

Child Health Corporation of America (CHCA) is a legacy business alliance of children's hospitals. CHCA children's hospitals represented more than 20,000 physicians, 100,000 employees, $14 billion in revenue and $1.8 billion in overall medical, surgical and pharmaceutical products. CHCA's former Owner Hospitals are North America's leading children's hospitals and are widely known for their excellence in caring for America's children. In 2011, CHCA, the National Association of Children's Hospitals and Related Institutions (NACHRI) and its public policy affiliate National Association of Children's Hospitals (N.A.C.H.) merged to pool our strengths and talents, creating a new organization, the Children’s Hospital Association. We share members, a common board of trustees and new President and CEO Mark Wietecha. As one Association, we will continue to be champions for children’s health.  

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company`s pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert`s proven intravitreal drug delivery platform has been safely administered to thousands of patients` eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.